ClinicalTrials.gg
RecruitingNCT07022821KETODEX-CSUpdated Jun 18, 2025

Comparison of Dexmedetomidine + Ketamine for Postoperative Pain in C-Section

A Phase 4 interventional study of Dexmedetomidine and ketamine in Postoperative Pain and Cesarean Section Pain, sponsored by Fatima Memorial Hospital. Recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Fatima Memorial Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies testing dexmedetomidine in Pain, Postoperative — 35 open to participants now, 38 under way, 5 of them phase 3. Dexmedetomidine · Pain, Postoperative.

Planned enrollment
51st of 136
90 · median 85
Started
2025
with 15 others
Phase 4
49 of 136
14 open now
Primary completion
2025-08
later than 8 of 37 live
Registered
107th of 136
by date

Among the 136 studies testing dexmedetomidine in Pain, Postoperative, this one is the 51st largest by planned enrollment, is one of 16 that started in 2025, is one of 49 in phase 4, reaches primary completion later than 8 of the 37 other live ones, and was the 107th registered.

Pain, Postoperative

5,675 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

35 of the 136 studies testing dexmedetomidine in Pain, Postoperative are open now, in 9 countries. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies testing dexmedetomidine in Pain, Postoperative, or all of them as a file.
02

Study summary

This study aims to compare three different doses of dexmedetomidine, when combined with a fixed dose of ketamine, for pain control in women undergoing cesarean section. The goal is to find the most effective combination with the fewest side effects.

Read the detailed description

Caesarean section is associated with moderate-to-severe postoperative discomfort in a significant proportion of women, which can delay recovery and return to regular activities, disrupt mother-child bonding, affect maternal psychological well-being, and impede nursing. Furthermore, inadequate surgical pain treatment may result in hyperalgesia and chronic pain. Due to widespread misconceptions that analgesic medications or procedures may have detrimental effects on the mother or newborn, and because the severity of post-caesarean section pain is typically underestimated, pain following caesarean section is frequently under-treated.

Various analgesic therapy techniques include oral or parenteral opioids, nonsteroidal anti-inflammatory medications, and neuraxial blocks with or without adjuvants, with unclear efficacy and/or substantial adverse effects. While opioids are the gold standard for postoperative pain management, they are associated with respiratory depression, nausea, vomiting, and other adverse effects that increase patient suffering. In recent years, there has been a shift toward minimizing opioid use and developing guidelines for enhanced postpartum recovery. Studies have explored combining opioids with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), ketamine, clonidine, and dexmedetomidine for effective pain relief while avoiding opioid-related side effects.

Dexmedetomidine, a highly selective α2-agonist, is beneficial in reducing tension and anxiety. It may be effective in the management of postoperative pain due to its analgesic properties. Dexmedetomidine acts at spinal and supraspinal sites, producing antinociceptive effects via stimulation of α2-receptors in the locus coeruleus.

Ketamine has been shown to be an effective painkiller with few side effects when used in small doses. Its analgesic effects result from N-methyl-D-aspartate (NMDA) receptor antagonism, and it also interacts with opioid receptors in the brain and spinal cord. When combined with benzodiazepines, ketamine's adverse effects are further minimized.

The combination of ketamine and dexmedetomidine offers several benefits, including hemodynamic stability, absence of respiratory depression, improved postoperative analgesia, and smoother recovery. Previous work has demonstrated a synergistic effect when these agents are used together, providing excellent symptom relief while minimizing side effects.

This study seeks to address the current gap in literature regarding the comparative efficacy of different doses of dexmedetomidine combined with a fixed dose of ketamine for post-cesarean analgesia. It aims to evaluate three infusion doses of dexmedetomidine combined with ketamine using postoperative pain scores as the primary outcome measure. The findings may help optimize pain management protocols following cesarean section

03

Conditions studied

  • Postoperative Pain
  • Cesarean Section Pain

Browse trials for

Keywords

  • Cesarean Pain
  • Multimodal Analgesia
  • Spinal Anesthesia
  • Dexmedetomidine
  • Ketamine
  • Postoperative pain
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Elective lower segment cesarean section
  • (ASA) Physical Status II
  • Provided

Exclusion criteria

Exclusion Criteria:

  • Known drug allergy
  • Presence of significant comorbidities
  • Emergency surgery
  • Documented psychiatric illness
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Low-Dose Dexmedetomidine

    Dexmedetomidine 0.2 µg/kg/hr + Ketamine 0.25 mg/kg/hr infusion

    Drug: Dexmedetomidine · Drug: ketamine

  • Experimental
    Medium-Dose Dexmedetomidine

    Dexmedetomidine 0.3 µg/kg/hr + Ketamine 0.25 mg/kg/hr infusion

    Drug: Dexmedetomidine · Drug: ketamine

  • Experimental
    High-Dose Dexmedetomidine

    Dexmedetomidine 0.4 µg/kg/hr + Ketamine 0.25 mg/kg/hr infusion

    Drug: Dexmedetomidine · Drug: ketamine

Interventions

  • Dexmedetomidine infusion at one of the following doses: Group A: 0.2 µg/kg/hr Group B: 0.3 µg/kg/hr Group C: 0.4 µg/kg/hr Route of Administration: Intravenous Frequency: Continuous infusion during postoperative period

  • Ketamine infusion at a fixed dose of 0.25 mg/kg/hr administered in all three groups. Route of Administration: Intravenous Frequency: Continuous infusion during postoperative period

06

What researchers measure

Primary outcomes

  1. Mean Postoperative Pain Score (Visual Analog Scale)

    Pain will be assessed using the Visual Analog Scale (VAS), a 10-point scale ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicate worse pain. Visual Analog Scale (VAS) scores will be recorded at 0, 2, 4, 6, 8, 12, 16, 20, and 24 hours postoperatively.

    Time frame: 0-24 hours post-surgery

Secondary outcomes

  1. Time to First Rescue Analgesia

    Measured in hours from the end of surgery to the time when the first dose of rescue analgesia (Nalbuphine 0.1 mg/kg Intravenous) is administered. Time will be recorded prospectively by anesthesia staff using standardized postoperative monitoring sheets and confirmed from the medication administration records.

    Time frame: Continuous monitoring up to 24 hours postoperative

  2. Total dose of rescue analgesia (Nalbuphine) required within 24 hours

    Determined from direct observation and recorded in structured data collection forms by trained anesthesia personnel during the postoperative period. All doses of Nalbuphine administered will be documented in real-time and verified against the patient's medication administration records and nursing charts.

    Time frame: 24 hours postoperative

07

Study locations

1 of 1 sites recruiting
  • Department of Anesthesiology, Fatima Memorial Hospital
    Lahore, Punjab 54000, Pakistan
    Recruiting
    • Ahmed Naeem, MBBS · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — VAS scores, rescue drug doses, vitals (de-identified)

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After publication (1 year post study completion)

Access criteria: On reasonable request by clinical researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2025, 3 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 3 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2025
First posted
Jun 15, 2025
StartActual
May 16, 2025
Primary completionEst.
Aug 16, 2025
CompletionEst.
Aug 31, 2025
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07022821
Lead sponsor
Fatima Memorial Hospital
Responsible party
Ahmed Naeem (Principal Investigator, Fatima Memorial Hospital) — Principal investigator
First posted
Jun 15, 2025
Start date
May 16, 2025
Primary completion
Aug 16, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Jun 18, 2025

Study contacts

Ahmed Naeem, MBBS
Contact
2505.ahmed@gmail.com
+923114681512

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Ketamine

Start the discussion